Datar Gandhar K, Khabusheva Elmira, Anand Archish, Beale Joshua, Sadek Marwa, Chen Chun-Wei, Potolitsyna Evdokiia, Alcantara-Contessoto Nayara, Liu Guangyuan, De La Fuente Josephine, Dollinger Christina, Guzman Anna, Martell Alejandra, Wohlan Katharina, Maiti Abhishek, Short Nicholas J, Yi S Stephen, Andresen Vibeke, Gjertsen Bjørn Tore, Falini Brunangelo, Rau Rachel E, Brunetti Lorenzo, Sahni Nidhi, Goodell Margaret A, Riback Joshua A
Medical Scientist Training Program, Baylor College of Medicine, Houston, TX, USA.
Cancer and Cell Biology Graduate Program, Baylor College of Medicine, Houston, TX, USA.
bioRxiv. 2025 May 28:2025.05.23.655671. doi: 10.1101/2025.05.23.655671.
During cancer development, mutations promote gene expression changes that cause transformation. Leukemia is frequently associated with aberrant expression driven by translocations in nucleoporin genes or , and mutations in . How disparate mutations converge on this regulatory pathway is not understood. Here we demonstrate that mutant NPM1 (NPM1c) forms nuclear condensates in multiple human cell lines, mouse models, and primary patient samples. We show NPM1c phase separation is necessary and sufficient to coordinate the recruitment of NUP98 and KMT2A to condensates. Through extensive mutagenesis and pharmacological destabilization of phase separation, we find that NPM1c condensates are necessary for regulating gene expression, promoting expansion, and maintaining the undifferentiated leukemic state. Finally, we show that nucleoporin and KMT2A fusion proteins form condensates that are biophysically indistinguishable from NPM1c condensates. Together, these data define a new condensate underlying leukemias that we term coordinating bodies (C-bodies), and propose C-bodies as a therapeutic vulnerability.
在癌症发展过程中,突变会促进基因表达变化,从而导致细胞转化。白血病常与核孔蛋白基因易位驱动的异常表达相关,以及 中的突变。不同的突变如何汇聚到这条调控途径尚不清楚。在这里,我们证明突变型NPM1(NPM1c)在多种人类细胞系、小鼠模型和原发性患者样本中形成核凝聚物。我们表明NPM1c相分离对于协调NUP98和KMT2A募集到凝聚物中是必要且充分的。通过广泛的诱变和相分离的药理学不稳定化,我们发现NPM1c凝聚物对于调节基因表达、促进 扩增和维持未分化的白血病状态是必要的。最后,我们表明核孔蛋白和KMT2A融合蛋白形成的凝聚物在生物物理学上与NPM1c凝聚物无法区分。总之,这些数据定义了一种新的白血病潜在凝聚物,我们称之为协调体(C体),并提出C体是一个治疗靶点。